Viridian Therapeutics, Inc.\DE
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenues: | ||||
| Product revenue, net | $24,671 | $— | $24,671 | $— |
| License revenue | 125 | 70,000 | 364 | 70,000 |
| Collaboration revenue(1) | 956 | 570 | 1,142 | 717 |
| Total revenues | 25,752 | 70,570 | 26,177 | 70,717 |
| Operating expenses: | ||||
| Cost of revenues | 1,527 | — | 1,527 | — |
| Research and development(2) | 70,093 | 86,261 | 219,301 | 249,721 |
| Selling, general and administrative | 57,609 | 24,322 | 151,263 | 61,642 |
| Total operating expenses | 129,229 | 110,583 | 372,091 | 311,363 |
| Loss from operations | (103,477) | (40,013) | (345,914) | (240,646) |
| Other income (expense), net: | ||||
| Interest income | 9,537 | 5,521 | 25,899 | 19,607 |
| Interest expense | (9,273) | (560) | (21,042) | (1,666) |
| Change in fair value of derivative liability | 2,070 | — | 8,410 | — |
| Other income (expense), net | (66) | 453 | (582) | 459 |
| Total other income, net | 2,268 | 5,414 | 12,685 | 18,400 |
| Net loss | $(101,209) | $(34,599) | $(333,229) | $(222,246) |
| Net loss per share, basic and diluted, common stock | $(0.81) | $(0.34) | $(2.75) | $(2.22) |
| Weighted-average common shares outstanding, basic and diluted | 113,407,432 | 81,784,499 | 107,875,408 | 81,576,987 |
| Net loss per share, basic and diluted, Series A convertible preferred stock | $(53.76) | $(22.96) | $(183.26) | $(147.81) |
| Weighted-average Series A convertible preferred shares outstanding, basic and diluted | 133,191 | 134,864 | 134,263 | 134,864 |
| Net loss per share, basic and diluted, Series B convertible preferred stock | $(53.76) | $(22.96) | $(183.26) | $(147.81) |
| Weighted-average Series B convertible preferred shares outstanding, basic and diluted | 48,463 | 145,160 | 66,004 | 145,160 |
| Comprehensive loss: | ||||
| Net loss | (101,209) | $(34,599) | $(333,229) | $(222,246) |
| Other comprehensive income (loss): | ||||
| Unrealized gain (loss) on available-for-sale securities | (1,020) | 294 | (2,626) | 373 |
| Foreign currency translation adjustment | (28) | — | (22) | — |
| Total other comprehensive income (loss) | (1,048) | 294 | (2,648) | 373 |
| Comprehensive loss | $(102,257) | $(34,305) | $(335,877) | $(221,873) |
(1)Includes related party amount of $0 and $186 for the three and nine months ended September 30, 2026, respectively, and $570 and $717 for the three and nine months ended September 30, 2025.
(2)Includes related party amount of $0 and $1,500 for the three and nine months ended September 30, 2026, respectively, and $0 and $4,528 for the three and nine months ended September 30, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.